Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.87 AUD | -0.92% | -0.50% | -2.94% |
Apr. 30 | Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases | MT |
Apr. 24 | Germany's Evotec Appoints Permanent CEO | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 73.78 and 25.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Leisure & Recreation
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.94% | 1.27B | C | ||
+8.06% | 4.2B | D+ | ||
+21.93% | 2.06B | C | ||
-.--% | 1.73B | - | ||
-22.36% | 1.51B | C+ | ||
-12.88% | 1.36B | - | ||
-8.72% | 1.17B | C- | ||
-18.52% | 1.14B | - | ||
-.--% | 818M | - | - | |
+4.15% | 538M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EVT Stock
- Ratings EVT Limited